Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.

Slides:



Advertisements
Similar presentations
Cindy Powers Magrini, PharmD, BCPS
Advertisements

Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
13 Principles of Effective Addictions Treatment
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy Kevin S. Flanigan, MD Medical Director Office of MaineCare.
 William Frank Barker, LPC, MAC Diane Diver, LMSW, CAC II.
Swinomish Wellness Program
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
What are “opiates”? heroin Morphine MS Contin oxycodone Oxycontin & Percocet hydrocodone Vicodin Codeine Tylenol # 3 hydromorphone Dilaudid meperidine.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
MEDICATION ASSISTED TREATMENT for OPIATE DEPENDENCY WHAT WORKS? SHELLEY ASKEW FLOYD, MS DIRECTOR OF PHARMACOTHERAPY SERVICES PYRAMID HEALTHCARE, INC.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Kristie R. Schmiege, MPH, CCS, CADC, CPC-M Director of Substance Abuse Services Genesee County Community Mental Health May 18,
Residential Treatment: What’s Methadone Got To Do With It? Siara Andrews, Psy.D. 1 Yong S. Song, Ph.D. 1 Steve Myers 2 University of California at San.
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
1 Advancing Recovery: Baltimore Buprenorphine Initiative Tucson Presentation July 29, 2009 Baltimore Substance Abuse Systems.
DOUGHNUTSDOUGHNUTS. Opioid Agonist Therapy The Skinny on Methadone et al.
Pharmacologic Treatment of Addiction
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
Good Prescribing to support Criminal Justice Interventions
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, MA Deputy Director 2/23/20151.
OPIOID SUBSTITUTION THERAPY
Opioid addiction treatment: Challenges (and opportunities) for community practice Marc Fishman MD.
For Pain or Not for Pain: Methadone Madness
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Study Finds Persons Who Fill Buprenorphine Prescriptions Have Higher Rates of Medical Conditions Associated with Pain and Comorbid Psychiatric Disorders.
HIGH POINT TREATMENT CENTER High Point Treatment Center’s (H.P.T.C.) mission is to prevent and treat chemical dependency and provide therapeutic services.
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
The Counseling Center, Inc. Devoted to the prevention and treatment of alcoholism and other drug addictions. We promote opportunities for individuals and.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
1 Performance Measurement for Medication-Assisted Treatment with Buprenorphine: Translating Evidence-Based Practices Such as Medication- Assisted Treatment.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
HELP. HOPE. HEALING. Understanding Medication Assisted Treatment Joan R. Shepherd, FNP The Coleman Institute.
FAMILY RECOVERY NETWORK EVENT: What is Substance Abuse Treatment? Patrick Seche, MS, CASAC Strong Recovery Addiction Psychiatry Division Department of.
Medication Assisted Treatment for Opioid Use Disorders
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Gregory S. Brigham, Ph.D., CEO
Medical Assisted Treatment
Medication Assisted Treatment
Opioid Medication Assisted Tx (1)
Integrating Care Through Partnerships – Missouri’s Experience
Medication-Assisted Therapy at Coleman Profession Services
McLean Hospital Division of Alcohol and Drug Abuse
Nick Szubiak, MSW, LCSW Director, Clinical Excellence in Addictions
MEDICATION ASSISTED TREATMENT for OPIATE ADDICTION
A State Targeted Response to the Opioid Crisis:
Pain Management: Patients Maintained on Buprenorphine
Ten Pearls for Medication Assisted Treatment of Opiate Use Disorders
Addiction Treatment Program North Canyon Medical Center
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.
Strategic Initiatives to Address Opioid Overdose & Addiction
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Transforming the Delivery of Substance Use Disorder Treatment in States Update August 2019.
Presentation transcript:

Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009

Suboxone and Opioid Trends Suboxone treatment for opioid dependence Limitations of Suboxone in WA State Development of HMC Suboxone Program –Blending of medication assisted Rx and traditional drug treatment Trends in prescription opioid use and problems HMC efforts to improve opioid management

used to be

Your Brain on Drugs Today 1-2 Min YELLOW shows places in brain where cocaine goes (striatum) Front of Brain Back of Brain Fowler et al., Synapse, 1989.

Addiction as a Brain Disease Key brain pathways involve motivation, salience, memory, and reward Prolonged drug use is associated with changes brain function Changes are pervasive and persist after drug use stops Brain changes demonstrated at molecular, cellular, structural and functional levels These studies provide a rationale for medication- assisted treatment of addiction

Opioid Dependence Treatment Methadone Maintenance is best studied Methadone treatment reduces: –Overall and overdose deaths –Drug use –Criminal behavior –Spread of infectious diseases (HIV, TB) Methadone may not be used for addiction treatment outside specially licensed programs

Methadone Maintenance Treatment Higher dose treatment improves outcomes Longer duration of treatment improves outcomes Psychosocial services improve outcomes Poor outcomes after discharge from treatment Maintenance superior to supported detox

Methadone Maintenance Limitations –Highly structured program (6 days/week) –Limited clinical flexibility and medical services –Expansion often opposed, stigma Ask Methadone Maintenance patients about: –Urine test results, take-home doses –Encourage adequate dose, treatment retention

Suboxone for Opioid Addiction New medication for opioid dependence Federal legislation (DATA 2000): –Allows trained MDs to prescribe Schedule III-V drugs approved for addiction treatment –Initially limited to 30 patients/group practice, but now each MD can treat up to 100 patients Safer than methadone With naloxone, reduced abuse potential

Activity Log Dose of Opioid Full Agonist Partial Agonist Antagonist Full Agonist vs Partial Agonist

Zubieta et al., 2000

Buprenorphine Superior to psychosocial treatment alone Longer treatment duration is more effective Comparable to MMT on most outcomes Not as good at retaining patients Medication cost higher than MMT, but total costs hard to compare in different settings Patients with co-morbid pain and addiction may benefit from physician management

Opioid Dependence Treatment Detoxification alone has low success rates No clear guidance on choosing between methadone maintenance and buprenorphine Prescribing buprenorphine requires specific training (8 hours) and a federal waiver Integration with psychosocial treatment is key Buprenorphine access limited by availability of MDs, insurance

Washington State Suboxone Policy Limited coverage for CNP, GAU patients Requires enrolment in state certified addiction program and prior authorization Limited to 6 months with one 6-month extension possible after clinical review Maintenance treatment and treatment for pain not covered Some Medicare Part D plans allow unlimited treatment

Suboxone at Harborview Initial experience: NIDA trial in primary care Program development with RWJ funding –Piloted in public primary care settings –Public funding with Counseling through ETS Program limitations –Many steps to enter treatment –Quick access difficult in busy public clinics –Separate counseling challenging

Harborview Addictions Program State certified intensive outpatient program “Abstinence-based” with 12-step support Strong co-occurring treatment track Multiple services (work, child care, housing) Few patients with opioid addiction Integrated psychiatric services, so comfortable with medications

Blending Treatment Models Tension between “abstinence” and harm reduction Limitation in treatment duration favors more intensive approach Emphasis on group versus individual treatment (no benzos, even prescribed) Differences in expectations Program size

HMC Suboxone Program Services Integrated medical and psychatric care Two 1.5 hour groups per week Medication dispensing after group One on one counseling Regular urine testing Early review of treatment progress

Treatment Continuation Options Abstinence with sober support (AA/NA) Methadone maintenance In-patient treatment with or w/o Suboxone For patients with pain and addiction, return to primary care opioid management if stable If insurance allows, transfer to primary care Suboxone treatment

Optimal Patient Selection Short addiction duration or significant recovery without medication assistance No benzodiazepine problem or use, even prescribed Not ambivalent about wanting to stop using all drugs and alcohol Co-morbid medical, psychiatric, pain OK Drug Court is a good match

HMC Suboxone Program Accepts patients with public funding Developed within WA State policy limitations Unique blending of treatment approaches Best for patients who are working toward recovery without medication assistance Options for continued medication-assisted treatment are limited